ABSTRACT

Objectives
To explore the impact on daily life of symptoms experienced by those with systemic autoimmunity associated with rheumatoid arthritis (RA).
Methods
Fifteen people took part in focus groups to explore the impact of symptoms on daily life.
Results
Core themes included: 1) physical impact of limited hand function and mobility; 2) psychological distress experienced included a fear of symptoms progressing into RA, uncertainty about the future, feelings of despair, shame and frustration.
Conclusion
People with arthralgia at risk of developing RA experienced considerable physical and psychological impact of symptoms. Greater consideration should be given to the needs of people at risk of developing RA.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes pain and functional impairment, which has a large impact on daily lives. Early identification and treatment improves prognosis. (van der Linden et al. 2010) To be able to identify people who will develop RA in the future, the EULAR study group for risk factors of RA recommended identification and assessment of symptoms in those with arthralgia and during the earliest phases of clinical arthritis as a research priority. (Gerlag et al. 2012) We have recently described the breadth of symptoms that persons at risk of RA might experience in the symptomatic at-risk phase. (Stack et al. 2014 ) Knowledge of these symptoms can facilitate the development of prediction tools and outcome measurement in arthralgia, ultimately leading to better prediction of who will develop RA. (van de Stadt et al. 2013 ) However, the early identification of those at risk, means that people are subject to investigations earlier, and have greater awareness of their at risk status.
Furthermore, people in the earliest phases of disease may have healthcare needs that need to be addressed while being monitored (either as part of a research cohort, or in a routine healthcare setting). A recent report by Dures et al highlights the gap between the need for psychological support in early RA patients and the provision of support by rheumatology clinicians and GPs. (Dures et al. 2014a; Dures et al. 2014b) The impact of early and established RA on a patient's daily life is well researched, (Bacconnier et al. 2015; Bernatsky et al. 2010; Bury 1982; Gossec et al. 2011; Shaul 1997) but the impact and consequences of symptoms among people with increased risk of RA prior to the onset of synovial swelling have never been described and might be overlooked. We describe the impact of symptoms on daily life of people at increased risk of RA.
METHODS
This report extends earlier explorations from a qualitative study on people at risk of RA and in patients with early RA to identify symptom complexes. (Stack, van Tuyl, Sloots, van de Stadt, Hoogland, Maat, Mallen, Tiwana, Raza, & van 2014) to 90 minutes and were analysed according to the inductive thematic analysis method to identify core themes in the qualitative data which explored the impact of arthralgia on daily living. (Stack, van Tuyl, Sloots, van de Stadt, Hoogland, Maat, Mallen, Tiwana, Raza, & van 2014) The transcripts where analysed by two independent researchers (LvT, MS) and one patient research partner (BM) who systematically searched for themes in the first group, forged connections between themes, then moved on to the next group. After all transcripts were analysed, the two independent researchers and patient research partner compared their results. Differences were discussed until consensus was reached and both researchers agreed to the same set of major themes. Further data exploration created new categories, which were grouped in the themes. Coding was facilitated using NVivo software for qualitative data analysis.
RESULTS
A total of 15 individuals participated in one of three focus group discussions with two times 4 and one time 7 participants. Participants were 11 females, mean age 54 years with a mean duration from symptom onset of 12 months; two used NSAIDs plus hydroxychloroquine, five used NSAIDs only and the remaining eight did not use any drugs for arthralgia (Table 1) . This paper is focused on daily impact of symptoms on daily living, therefore, the themes extracted explored the physical impact and psychological impact of symptoms. Quotes supporting the themes are presented in Table 2 , with physical impact quotes coded Ph1.1 to Ph1.7 and psychological impact quotes coded as Psy2.1 to Psy6.1, with 2 to 6 referring to different subthemes of psychological impact. When quotes are part of a conversation, the different participants are referred to as A, B or C, and the moderator as 'Mod'.
Physical impact
Participants described symptoms which led to a decrease in physical functioning and decreased participation in everyday activities. Activities such as dressing, washing, eating and household chores were impaired. Participants particularly described having problems with hand function (Ph1.1 -1.4) and a decreased mobility (Ph1.5 -1.6).
The impact of physical symptoms could be so severe, that participants described the psychological distress that physical symptoms had caused as reflected in quote Ph1.7.
Psychological impact
There was a general feeling of fear and uncertainty amongst the participants when describing their symptoms, as they did not know if they were at the beginning of something worse to come (i.e. RA). Several participants described the fear of future development of RA as the worst part of their condition (Psy2.1 -2.3) which was closely linked to the described uncertainty about the progression of symptoms to RA in the future, influencing participants' decisions in life and making them feel limited (Psy3.1 -3.5). Other described emotions included feelings of shame (Psy4.1), frustration (Psy5.1) and despair (Psy6.1).
To get a better understanding of the group of 15 participants as compared to the entire cohort of 487 participants, we compared the distribution of tender joint counts (in 53 joints), pain score (VAS scale from 0 to 100) and duration of complaints, all at cohort entry. While the focus group participants had a significantly higher tender joint count at cohort entry compared to the rest of the cohort (median 11 vs 4), both pain score and symptom duration were highly similar (VAS 32 vs VAS 35; 12 months vs 12 months).
DISCUSSION
The disruptive impact of RA on a patient's life is increasingly documented, but the impact of symptoms among people at risk of RA has never been described. Here we report on the impact of symptoms on the daily lives of anti-CCP antibody positive individuals at risk of developing RA. While the physical impact of symptoms was expected, the severity and complexity of the psychological impact of early symptoms was remarkable. Psychological distress in the form of fear, uncertainty, shame, frustration and despair in those at risk dominated the group discussions. Physicians and researchers need to realize the impact of musculoskeletal symptoms on the daily lives of anti-CCP antibody positive individuals, especially since these people may not have access to services offered to those with a confirmed diagnosis and cannot be treated with drugs with proven efficacy.
The participants that joined the discussions are part of the Reade arthralgia cohort. They are aware of their increased risk of RA and are voluntarily visiting the rheumatology clinic on a yearly basis to monitor their risk. This subgroup of people that volunteered to join a focus group discussion on perceived symptoms may differ from the larger cohort.
The high tender joint count among focus group participants might imply an increased psychological impact of the symptoms in this selected group as compared to the rest of the cohort. Alternatively, comorbid conditions might have influenced the perceived physical or psychological impact of symptoms. Further exploratory investigations are needed to fully understand the needs in subgroups of people at increased risk of RA.
Nevertheless, the described impact of musculoskeletal symptoms in anti-CCP antibody positive individuals on everyday life is substantial and should not be neglected.
It is important to understand where the psychological distress among these anti-CCP antibody positive individuals comes from in order to provide help. If making people aware of their increased risk of RA induces psychological distress, we might need to provide people with resources to deal with this information. About 35% of patients in our at-risk cohort go on to develop RA.
[5] For this selected group, it is beneficial to be identified and treated as early as possible. But for the remaining 65% that never continue to develop RA, the benefit/risk ratio will be negative and the figurative 'sword of Damocles' might induce a complex spectrum of psychological distress. Like the patients that go on to develop RA, these people might benefit from psychological services and support, as well as from treatment directed at pain or other perceived symptoms.
Although focus group discussions were continued until saturation was reached, the primary purpose of the discussions was to investigate the symptoms that people with arthralgia experience, not the impact of symptoms. The impact of symptoms on daily life unexpectedly dominated the discussions. More in-depth research is needed to investigate the impact of arthralgia symptoms in other cohorts and other countries. To this end, we are currently developing a quantitative questionnaire to measure the type, severity and impact of symptoms in persons at risk of RA in order to explore commonality and prevalence of symptoms in people at risk of RA. 
CONFLICT OF INTEREST STATEMENT
The authors have no competing interests regarding this work 
